What is the difference between single sign-on and separate logins for clinical trial sites?

Why the Access Model Matters at a Clinical Trial Site

The difference between single sign-on and separate logins is not just convenience. In a clinical trial environment, it affects how quickly coordinators, investigators, monitors, and vendors can move between systems, how reliably access is granted and revoked, and how often users resort to weak password habits or workarounds. The access model also shapes auditability, because a fragmented login estate is harder to review consistently than a centralised one.

Separate logins can be defensible when applications are isolated or governed by different sponsors, but they raise the cost of routine tasks and increase the chance of orphaned access. Single sign-on can improve user experience and governance, but only when the trust relationship between the identity provider and each study application is well controlled. For a broader identity governance perspective, NIST’s NIST SP 800-63 Digital Identity Guidelines remains a useful reference point for assurance and federation design. In practice, many site teams discover the operational burden of separate logins only after staff begin reusing passwords or delaying access requests because the process has become too cumbersome.

How SSO and Separate Logins Behave Across Study Portals

Single sign-on centralises authentication, so the user proves their identity once and then reaches multiple approved applications without repeated prompts. That does not mean every action is automatically trusted. Each study portal still needs its own authorisation rules, role checks, and session controls, and the federation layer must be configured so that the right account maps to the right site role. The value is strongest when the same user must move frequently between EDC, eTMF, eISF, safety, and query-resolution tools during the day.

Separate logins push that complexity back onto the user and the site team. Every portal may have its own password policy, reset process, lockout behaviour, and review cycle. That increases support effort and makes joiner-mover-leaver administration slower, especially when sites work with rotating study staff or contract personnel. If access is not removed promptly, separate credentials can linger long after the user’s need has changed. Single sign-on reduces that sprawl, but it also concentrates risk: if federation, identity proofing, or session handling is weak, one failure can affect multiple applications at once.

• Use single sign-on when users genuinely need repeated access across several study systems and governance can be centralised.
• Use separate logins when applications are tightly segregated, sponsor requirements differ, or trust relationships cannot be validated cleanly.
• Require role-based authorisation in either model, because authentication alone does not control study access.
• Verify that offboarding, password reset, and session timeout rules are consistent with site operating procedures.

The model breaks down when the federation layer is treated as a convenience feature rather than a governed access control boundary.

Where Clinical Trial Teams Misjudge the Trade-off

Tighter access centralisation often improves control, but it also increases dependency on the identity platform, so teams have to balance operational simplicity against blast radius and vendor reliance. The usual mistake is to compare only login friction and ignore how changes, exceptions, and emergency access will actually be handled across the study lifecycle.

One common edge case is mixed governance. A sponsor may want centralised sign-on for efficiency, while a site or vendor application still requires separate local accounts for contractual or validation reasons. That is not necessarily a failure of SSO; it is a sign that trust boundaries differ by system. Another edge case is regulated downtime. If the shared identity service is unavailable, SSO can temporarily block multiple study tools at once, whereas separate logins may preserve partial access. The industry does not fully agree on whether that resilience benefit outweighs the operational overhead, because the answer depends on how critical uninterrupted access is and how mature the fallback process is.

For most sites, the better question is not which model is universally safer, but which one preserves accountability without creating avoidable access friction. If users cannot complete routine study work cleanly, they will bypass the designed process in some other way.

Practitioner Guidance

What to prioritise: Treat the access model as an operating decision, not just an IT preference. The first check is whether the site can prove timely joiner-mover-leaver handling across every application the user reaches, because that is where governance often succeeds or fails.

What to verify: Confirm that single sign-on does not blur application-level accountability. Each portal should still enforce its own role restrictions, logging, and session boundaries, and each exception path should be documented so auditors can see how access was granted and removed.

Common mistake: Choosing separate logins because they feel simpler to approve locally, then discovering that the organisation has multiplied password resets, inconsistent reviews, and stale accounts across the study estate. The practitioner takeaway is that the right model is the one that makes access control more reliable in day-to-day operations, not the one that merely looks easier at procurement time.

Related resources from NHI Mgmt Group

• What is the difference between single-instance SaaS and multi-tenant SaaS for CIAM?
• What is the difference between MFA and single sign-on for reducing authentication risk?
• What is the difference between passwordless authentication and single sign-on for frontline access?
• What is the difference between single sign-on and privileged password management in enterprise access design?